Infectious Diseases (INF)

P-028 - CONTINUOUS RENAL REPLACEMENT THERAPY ENCHANCES CEFTRIAXONE CLEARANCE BUT ONCE-DAILY DOSING MAY BE SUFFICIENT.

P-049 - PHARMACOKINETICS AND PHARMACODYNAMICS OF CASIRIVIMAB AND IMDEVIMAB IN A DOSE-RANGING STUDY IN OUTPATIENTS WITH COVID-19.

P-061 - PHARMACOKINETICS AND PHARMACODYNAMICS OF CASIRIVIMAB AND IMDEVIMAB IN OUTPATIENTS WITH COVID-19.

P-062 - A MECHANISM-BASED MODEL (MBM) TO DESCRIBE THE SYNERGISTIC EFFECT OF POLYMYXIN B (PMB) and FOSFOMYCIN (FOF) IN KLEBSIELLA PNEUMONIAE (KP).

P-071 - PHARMACOKINETICS AND IMMUNOGENICITY ASSESSMENT OF A SINGLE SUBCUTANEOUS DOSE OF CASIRIVIMAB AND IMDEVIMAB IN HOUSEHOLD CONTACTS OF SARS-COV-2 INFECTED PERSONS.

P-105 - THE RELATIONSHIP BETWEEN HIGH DENSITY LIPOPROTEIN CHOLESTEROL AND SEPSIS: A CLINICAL AND GENETIC APPROACH.

P-181 - AMPICILLIN (AMP) AND CEFTRIAXONE (CRO) DOSING FOR CHILDREN WITH PNEUMOCOCCAL COMMUNITY-ACQUIRED PNEUMONIA USING MONTE CARLO (MC) AND PHYSIOLOGIC BASED PHARMACOKINETIC (PBPK) SIMULATIONS.

P-182 - PHARMACOKINETICS AND PHARMACODYNAMICS OF CASIRIVIMAB AND IMDEVIMAB IN HOSPITALIZED PATIENTS WITH COVID-19.

PT-010 - WEIGHT-BASED DOSING IS NOT NEEDED FOR RIFAMPICIN FOR PATIENTS WITH TUBERCULOSIS (TB): PK EVIDENCE FROM TBTC STUDY S31/A5349 (STUDY S31).

PT-010 - WEIGHT-BASED DOSING IS NOT NEEDED FOR RIFAMPICIN FOR PATIENTS WITH TUBERCULOSIS (TB): PK EVIDENCE FROM TBTC STUDY S31/A5349 (STUDY S31).

PW-018 - KINETICS OF ANTI-SARS-COV-2 ANTIBODY RESPONSE AFTER BNT162B2 VACCINATION IN HEALTHCARE WORKERS: THE RESULTS OF SIX MONTHS OF FOLLOW-UP.

LB-006 - APPLICATION OF PHARMACOKINETIC MODELING & SIMULATION IN DEVELOPMENT OF A LONG-ACTING ANTIBODY (EVUSHELD) COMBINATION FOR THE POTENTIAL PREVENTION AND TREATMENT OF COVID-19.